The New England Journal of Medicine

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...
News Medical

Study points to potential treatment for thrombotic thrombocytopenic purpura

A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of ...
Monthly Prescribing Reference

Adzynma Approved for Congenital Thrombotic Thrombocytopenic Purpura

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...
Nasdaq

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...
Monthly Prescribing Reference

Cablivi Approved for Pediatric Acquired Thrombotic Thrombocytopenic Purpura

Results showed 80% of pediatric patients achieved clinical remission. The Food and Drug Administration (FDA) has expanded the approval of Cablivi ® (caplacizumab-yhdp) to include treatment of ...
News Medical

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ...
The American Journal of Managed Care

Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD, details the typical ...
The American Journal of Managed Care

Unmet Need Remains in iTTP Treatment, but Caplacizumab Could Be Major Step Forward

A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated ...
Healio

Caplacizumab effective in acquired thrombotic thrombocytopenic purpura

Please provide your email address to receive an email when new articles are posted on . Patients with acquired thrombotic thrombocytopenic purpura experienced a faster normalization of platelet count ...
Nature

Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...
Healio

Low-dose rituximab induces high response rates in acquired thrombotic thrombocytopenic purpura

Please provide your email address to receive an email when new articles are posted on . Adjuvant low-dose rituximab in combination with plasma exchange and steroids appeared effective for the ...
Business Wire

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...